Geron (NASDAQ:GERN) Issues Quarterly Earnings Results

Geron (NASDAQ:GERN) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04), Zacks reports. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million.

Geron Price Performance

Shares of NASDAQ GERN traded down $0.01 during trading hours on Friday, reaching $1.74. 1,725,814 shares of the stock traded hands, compared to its average volume of 14,364,052. The company has a market capitalization of $1.05 billion, a P/E ratio of -5.42 and a beta of 0.53. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a 52-week low of $1.46 and a 52-week high of $5.34. The company’s 50-day simple moving average is $2.97 and its two-hundred day simple moving average is $3.80.

Analyst Ratings Changes

Several research analysts have commented on GERN shares. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and cut their target price for the stock from $3.50 to $2.00 in a research note on Thursday. Scotiabank lowered their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Stifel Nicolaus lowered their price target on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Barclays reaffirmed an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $5.68.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.